<doc>
  <docmeta id="113hr3089ih">
    <bill congress="113" type="hr" number="3089" version="ih"/>
    <revision size="48141" annotations="0" status="complete" id="5" commit-time="2013-09-18T15:04:07Z" committer="mbohmer" doc="113hr3089ih/5.xml">
      <description>Edited via AKN</description>
    </revision>
  </docmeta>
  <bill bill-stage="Introduced-in-House" bill-type="olc" dms-id="H55533685867648E38240CEDB6C47E824" public-private="public">
	<metadata>
<dublinCore>
<title>113 HR 3089 IH: Compounding Clarity Act of 2013</title>
<publisher>U.S. House of Representatives</publisher>
<date>2013-09-12</date>
<format>text/xml</format>
<language>EN</language>
<rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</rights>
</dublinCore>
</metadata>
<form>
		<distribution-code display="yes">I</distribution-code>
		<congress>113th CONGRESS</congress>
		<session>1st Session</session>
		<legis-num>H. R. 3089</legis-num>
		<current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber>
		<action>
			<action-date date="20130912">September 12, 2013</action-date>
			<action-desc>
        <sponsor name-id="G000568">Mr. Griffith of
			 Virginia</sponsor> (for himself, <cosponsor name-id="D000197">Ms.
			 DeGette</cosponsor>, and <cosponsor name-id="G000410">Mr. Gene Green of
			 Texas</cosponsor>) introduced the following bill; which was referred to the
			 <committee-name committee-id="HIF00">Committee on Energy and
			 Commerce</committee-name>
      </action-desc>
		</action>
		<legis-type>A BILL</legis-type>
		<official-title>To amend section 503A of the Federal Food, Drug, and
		  Cosmetic Act with respect to pharmacy compounding.</official-title>
	</form>
	<legis-body id="H31A33BDC72FB461BB49B80E808A81040" style="OLC">
		<section id="H7B654A7D60D2494D9F040DA3F3F8BA1C" section-type="section-one">
      <enum>1.</enum>
      <header>Short title</header>
      <text display-inline="no-display-inline">This Act may be cited as the
			 <quote>
          <short-title>Compounding Clarity Act of
			 2013</short-title>
        </quote>.</text>
		</section>
    <section id="H50B0465A55DE49C4BA12301EAB9C9236">
      <enum>2.</enum>
      <header>
			 Traditional pharmacy compounding</header>
      <text display-inline="no-display-inline">
        <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
          <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A">Section 503A of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353a">
            <cato:entity-ref entity-type="uscode" value="usc/21/353a">21 U.S.C. 353a</cato:entity-ref>
          </external-xref>)</cato:entity> is amended to read as follows:</text>
			<quoted-block display-inline="no-display-inline" id="HB23B7FC6FB1D48DA9EFFB7148594AD97" style="OLC">
				<section id="HF6AD07C0BA4C46B4BA563BA301D43C75">
          <enum>503A.</enum>
          <header>Traditional
				pharmacy compounding</header>
					<subsection id="H46C677C3910E4AB68CF037DD7B1EA051">
            <enum>(a)</enum>
            <header>In
				General</header>
            <text>
              <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:501/ss:a/p:2/sp:B">Sections 501(a)(2)(B)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:f/p:1">502(f)(1)</cato:entity-ref>, and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505 of this Act</cato:entity-ref> and
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> shall not apply to a
				<italic/>drug product for human use if each of the following conditions
				is met:</text>
						<paragraph id="H70EE068232C54639B5A4C83926874EEB">
              <enum>(1)</enum>
              <header>Identified
				patient and receipt of prescription</header>
              <text display-inline="yes-display-inline">The drug product is compounded in
				accordance with one of the following:</text>
							<subparagraph id="HF1D5A74C8758475EBC1496D591058A60">
                <enum>(A)</enum>
                <header>In
				general</header>
                <text display-inline="yes-display-inline">The drug product is
				compounded by a licensed pharmacist in a State-licensed pharmacy or a Federal
				facility, or by a licensed physician, for an identified individual patient
				based on the receipt of a valid prescription.</text>
							</subparagraph>
              <subparagraph id="H3B4D146C45424C18B46DB01E8A107918">
                <enum>(B)</enum>
                <header>Anticipatory
				compounding</header>
                <text display-inline="yes-display-inline">The drug product
				is compounded by a licensed pharmacist in a State-licensed pharmacy or a
				Federal facility, or by a licensed physician, in limited quantities before the
				receipt of a valid prescription for an identified individual patient, based
				on—</text>
								<clause id="H91AD963F125C4901B6D2D3A4739E173A">
                  <enum>(i)</enum>
                  <text>historical demand
				for the drug product; and</text>
								</clause>
                <clause id="H82AEFF522A784499B18F99B719C3FE75">
                  <enum>(ii)</enum>
                  <text>a
				history of prescriptions for the drug product generated solely within an
				established relationship between the licensed pharmacist or licensed physician
				who is performing the compounding and—</text>
									<subclause id="H3FA354519C374145A7EA7D58FF10723A">
                    <enum>(I)</enum>
                    <text>the individual
				patient; or</text>
									</subclause>
                  <subclause id="H53856E85EE8340EDBEF284B598D23B27">
                    <enum>(II)</enum>
                    <text>the physician or
				other licensed practitioner who writes the prescription.</text>
									</subclause>
                </clause>
              </subparagraph>
              <subparagraph id="H194F7C5E33EC4B88955CA9166761DE7F">
                <enum>(C)</enum>
                <header>Compounding for
				office use</header>
                <text display-inline="yes-display-inline">The drug product
				is compounded by a licensed pharmacist in a State-licensed pharmacy or a
				Federal facility, or by a licensed physician, pursuant to a
				non-patient-specific purchase order and—</text>
								<clause id="H551DD76698D04184A99C47AD005D5BF3">
                  <enum>(i)</enum>
                  <text>the drug product
				will be administered by a health care practitioner within a physician’s office,
				a hospital, or another health care setting;</text>
								</clause>
                <clause id="H3FC96FDD95D346B8A067373091F44CE8">
                  <enum>(ii)</enum>
                  <text>valid
				patient-specific prescriptions or, when a compounded drug product is
				administered within the same health system in which it was compounded, valid
				patient names—</text>
									<subclause id="H145D328A4FC34B9DBBD4FBBBEEEC4C00">
                    <enum>(I)</enum>
                    <text>are submitted,
				electronically or otherwise, to the pharmacist or physician who performs the
				com­pound­ing, not later than 7 business days after the drug product is
				administered; and</text>
									</subclause>
                  <subclause id="H965178251B50454FA71FA3B46D68FA60">
                    <enum>(II)</enum>
                    <text>will, in the
				aggregate, account for the total volume of drug product compounded pursuant to
				the non-patient-specific purchase order;</text>
									</subclause>
                </clause>
                <clause id="H0D2E2863DADE4CFCB1B4D35F7545F2A9">
                  <enum>(iii)</enum>
                  <text display-inline="yes-display-inline">during any 6-month period, of the total
				drug products dispensed from the facility at which the drug product was
				compounded, not more than 5 percent are compounded sterile drug products that
				are—</text>
									<subclause id="HF7D4C0A12D764F039726C643F8769A1B">
                    <enum>(I)</enum>
                    <text>dispensed pursuant
				to this subparagraph; and</text>
									</subclause>
                  <subclause id="HBE27C64B2BFE49BD80674A247E861AC2">
                    <enum>(II)</enum>
                    <text>shipped
				interstate;</text>
									</subclause>
                </clause>
                <clause id="H62EE1CBB4E64448A92F649E94643A0CB">
                  <enum>(iv)</enum>
                  <text>records of the
				compounding will be kept for not less than 3 years; and</text>
								</clause>
                <clause id="H428D527521CB4F61BB4D99D0CBC16917">
                  <enum>(v)</enum>
                  <text>the statement
				<term>Office Use Only</term> and the statement <term>Not for resale</term>
				appear on the compounded drug product.</text>
								</clause>
                <continuation-text continuation-text-level="subparagraph">Compounding under this
				subparagraph shall not be considered to be in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:B/cl:ii" proposed="true">clause (ii)</cato:entity-ref> because
				of the failure of a pharmacist or a physician to account for valid
				patient-specific prescriptions or valid patient names as required by such
				clause, so long as the pharmacist or physician makes a good faith, reasonable
				effort to account for the prescriptions or names, as applicable, and does not
				continue to compound drug products under this subparagraph for a health care
				practitioner or facility with a history of failing to submit such prescriptions
				or patient names.</continuation-text>
              </subparagraph>
            </paragraph>
            <paragraph id="HC2547B71AF7D48968C15E62722715775">
              <enum>(2)</enum>
              <header>Quality
				standards</header>
              <text>Irrespective of whether a drug product is compounded
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>, <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:B" proposed="true">(B)</cato:entity-ref>, or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:C" proposed="true">(C) of paragraph (1)</cato:entity-ref>, the drug product is
				compounded, stored, and dated in compliance with the United States
				Pharmacopoeia chapters that are applicable to pharmaceutical compounding
				(including the chapter on sterile preparations).</text>
						</paragraph>
            <paragraph id="HA004360A49044345BB46A1E6527242EC">
              <enum>(3)</enum>
              <header>Bulk drug
				substances</header>
              <text>If the drug product is compounded using bulk drug
				substances (as defined in regulations of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> published at section
				207.3(a)(4) of title 21 of the Code of Federal Regulations (or any successor
				regulations))—</text>
							<subparagraph id="H05E7E7A1DE0B4D8486A88CE87AFB45BE">
                <enum>(A)</enum>
                <text>the bulk drug
				substances—</text>
								<clause id="H9B5EA96762CF4FCA9AC977BFB39B9671">
                  <enum>(i)</enum>
                  <text display-inline="yes-display-inline">if an applicable monograph exists under the
				United States Pharmacopoeia, the National Formulary, or another compendium or
				pharmacopeia recognized under Federal law, each comply with the
				monograph;</text>
								</clause>
                <clause id="H928FBA5CC4F843A392B923920DBE0351">
                  <enum>(ii)</enum>
                  <text>if such a
				monograph does not exist, each are drug substances that are components of drug
				products approved or licensed by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for human use; or</text>
								</clause>
                <clause id="HDC5598855DB14A1D906FF510B62F5D8C">
                  <enum>(iii)</enum>
                  <text>if such a
				monograph does not exist and the drug substance is not a component of a drug
				product so approved or licensed, each appear on a list published by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> (through regulations issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e" proposed="true">subsection (e)</cato:entity-ref>);</text>
								</clause>
              </subparagraph>
              <subparagraph id="H0FFDCD2D6CA04709A8C3A55914C142F3">
                <enum>(B)</enum>
                <text>the bulk drug
				substances are each manufactured by an establishment that is registered under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref> (including a foreign establishment that is registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510/ss:i">section
				510(i)</cato:entity-ref>); and</text>
							</subparagraph>
              <subparagraph id="HD758A1C6E65141E7AFC777BB35B94A4E">
                <enum>(C)</enum>
                <text>the bulk drug
				substances are each accompanied by a valid certificate of analysis.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H9645846F1B5F4131B9AF800FC3B4ACDD">
              <enum>(4)</enum>
              <header>Ingredients
				(other than bulk drug substances)</header>
              <text>If any ingredients (other than
				bulk drug substances) are used in compounding the drug product, such
				ingredients comply with the standards of an applicable United States
				Pharmacopoeia or National Formulary monograph.</text>
						</paragraph>
            <paragraph id="H1153EA146B86450A98EC03E200D228C2">
              <enum>(5)</enum>
              <header>Drug products
				withdrawn or removed because unsafe or not effective</header>
              <text>The drug
				product does not appear on a list published by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> of drug products
				that have been withdrawn or removed from the market because such drug products
				or components of such drug products have been found to be unsafe or not
				effective.</text>
						</paragraph>
            <paragraph id="HCD9E7F63D954488B9CC5F1563BAC55A7">
              <enum>(6)</enum>
              <header>Essentially a
				copy of a marketed and approved drug product</header>
              <text>The licensed
				pharmacist or licensed physician does not compound any drug product that is
				essentially a copy of a marketed and approved drug product.</text>
						</paragraph>
            <paragraph id="H83AC77959E9C4DC9A286D850B2A01EBF">
              <enum>(7)</enum>
              <header>Drug products
				presenting demonstrable difficulties for compounding</header>
              <text display-inline="yes-display-inline">The drug product is not identified
				(directly or as part of a category of drug products) in a list published by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> (through regulations issued under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e" proposed="true">subsection (e)</cato:entity-ref>) as a drug product
				that presents demonstrable difficulties for compounding that reasonably
				demonstrate an adverse effect on the safety or effectiveness of that drug
				product.</text>
						</paragraph>
            <paragraph id="H75462EA55CF34E59B0EC9FB2280AD1C1">
              <enum>(8)</enum>
              <header>Prohibition on
				wholesaling</header>
              <text display-inline="yes-display-inline">The drug product
				will not be sold by an entity other than the pharmacy or physician that
				compounded such drug product.</text>
						</paragraph>
          </subsection>
          <subsection commented="no" id="H18F948D7CF684AD6947370AA4D58E798">
            <enum>(b)</enum>
            <header>State
				regulation</header>
            <text display-inline="yes-display-inline">Nothing in this
				section shall prevent a State from—</text>
						<paragraph id="H7E1FF47A82174619A16E68CDF2D7C1D5">
              <enum>(1)</enum>
              <text>imposing
				restrictions on the type of compounding described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:B" proposed="true">subparagraph (B)</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:C" proposed="true">(C) of
				subsection (a)(1)</cato:entity-ref> that are in addition to the restrictions applicable under
				this section; or</text>
						</paragraph>
            <paragraph id="H8B60E8F3A8B445C4B59D4F7C2B6AF016">
              <enum>(2)</enum>
              <text>enforcing
				requirements or restrictions contained in the chapters or standards described
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:2" proposed="true">subsection (a)(2)</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <subsection id="H03A230652D6F43FDBDE3B5946739CAFC">
            <enum>(c)</enum>
            <header>Notification
				system</header>
						<paragraph id="HF5C5A7D91D5A4349AE94CFFBA7F30251">
              <enum>(1)</enum>
              <header>Development and
				implementation</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall develop and implement a system for receiving and reviewing submissions
				from State boards of pharmacy—</text>
							<subparagraph id="H87C2E54CCFC44A0181A8A6012BF6FA98">
                <enum>(A)</enum>
                <text>describing actions
				taken against compounding pharmacies; or</text>
							</subparagraph>
              <subparagraph id="H83F523D020294094A5DD4B1FA8608F62">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">expressing concerns that a com­pound­ing
				pharmacy may be acting in violation of one or more requirements of this
				section.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H5992D3662D8B4F7C953DAF4180709C9E">
              <enum>(2)</enum>
              <header>Content of
				submissions from State boards of pharmacy</header>
              <text>An action referred to
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:c/p:1/sp:A" proposed="true">paragraph (1)(A)</cato:entity-ref> is, with respect to a pharmacy that compounds drug
				products, any of the following:</text>
							<subparagraph id="H7BEBE02548F94DA8BA10909E6C2AC530">
                <enum>(A)</enum>
                <text>The issuance of a
				warning letter, or the imposition of sanctions or penalties, by a State for
				violations of a State’s pharmacy regulations pertaining to compounding.</text>
							</subparagraph>
              <subparagraph id="HF8B445C43C0E4A5CB16B73AC29743A85">
                <enum>(B)</enum>
                <text>The suspension or
				revocation of a State-issued pharmacy license or registration.</text>
							</subparagraph>
              <subparagraph id="HF2F40108DD69446E831A891C332EC7E6">
                <enum>(C)</enum>
                <text>The recall of
				compounded drug products due to concerns relating to the quality or purity of
				such products.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H2203CB6BB62845A8A626905C08447495">
              <enum>(3)</enum>
              <header>Consultation</header>
              <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall develop the system under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:c/p:1" proposed="true">paragraph (1)</cato:entity-ref> in consultation with the
				National Association of Boards of Pharmacy.</text>
						</paragraph>
            <paragraph commented="no" id="H0EA5E4163D0C41D8AADD77D7343BD0B0">
              <enum>(4)</enum>
              <header>Review and
				determination by Secretary</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall review each submission
				received under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:c/p:1" proposed="true">paragraph (1)</cato:entity-ref> and such other information as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				determines necessary (including information collected through an inspection or
				maintained in the Adverse Event Reporting System database) and make a
				determination as to whether the pharmacy involved may be in violation of one or
				more requirements of this section.</text>
						</paragraph>
            <paragraph id="H6A581C72E38D49368A3740C9D8B1172E">
              <enum>(5)</enum>
              <header>Notifying State
				boards of pharmacy</header>
              <text display-inline="yes-display-inline">The system
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:c/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall be designed to immediately notify State boards of
				pharmacy when—</text>
							<subparagraph id="HA2D734C7712246E5962A9C05B4FA4708">
                <enum>(A)</enum>
                <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				receives a submission under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:c/p:1" proposed="true">paragraph (1)</cato:entity-ref>; or</text>
							</subparagraph>
              <subparagraph id="HA85BAD3ABA694ADD8C3F7D0D711D4F82">
                <enum>(B)</enum>
                <text>the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				makes a determination that a pharmacy may be in violation of one or more
				requirements of this section.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H49E1C6341C084CCE89F830FD9028B3B6">
              <enum>(6)</enum>
              <header>Timing</header>
              <text>Not
				later than one year after the date of enactment of the
				<short-title>Compounding Clarity Act of
				2013</short-title>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall begin implementation of the system
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:c/p:1" proposed="true">paragraph (1)</cato:entity-ref>.</text>
						</paragraph>
          </subsection>
          <subsection id="H0D20C1A48DFE4D409F312F8532046F9A">
            <enum>(d)</enum>
            <header>Inspection
				authority</header>
            <text display-inline="yes-display-inline">In accordance with
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704/ss:a">section 704(a)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may inspect a pharmacy’s records to determine
				whether the pharmacy is in violation of one or more requirements of this Act
				if—</text>
						<paragraph id="H8D68E8ACFC044874BDDBCE5BD39CEF4A">
              <enum>(1)</enum>
              <text display-inline="yes-display-inline">the inspection is conducted in coordination
				with the relevant State board or boards of pharmacy; or</text>
						</paragraph>
            <paragraph id="H112E68E76B15475D8B7BFE16FA3DC30C">
              <enum>(2)</enum>
              <text display-inline="yes-display-inline">the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> has evidence that the
				pharmacy may be in violation of such a requirement.</text>
						</paragraph>
          </subsection>
          <subsection id="H5FCDC48C095C405EB00F144648104B45">
            <enum>(e)</enum>
            <header>Regulations</header>
						<paragraph id="H891E2FDC4D3443D7ABEC494A74FAB293">
              <enum>(1)</enum>
              <header>In
				general</header>
              <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall issue regulations to implement this
				section.</text>
						</paragraph>
            <paragraph id="HB309E93E60754F9C96D0910CCFC05EFF">
              <enum>(2)</enum>
              <header>Advisory
				committee on compounding</header>
              <text display-inline="yes-display-inline">Before issuing regulations to implement
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A/cl:iii" proposed="true">subsections (a)(3)(A)(iii)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:7" proposed="true">(a)(7)</cato:entity-ref>, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall convene and consult
				an advisory committee on compounding. The advisory committee shall include
				representatives from the National Association of Boards of Pharmacy, the United
				States Pharmacopoeia, pharmacists having current experience and expertise in
				compounding, physicians having background and knowledge in compounding, and
				consumer organizations with an expertise in compounding.</text>
						</paragraph>
            <paragraph id="H308358F736B5497D81DAF5E11950AE6D">
              <enum>(3)</enum>
              <header>Interim
				lists</header>
              <text display-inline="yes-display-inline">Before the date on
				which final regulations are issued to implement <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A/cl:iii" proposed="true">subsections (a)(3)(A)(iii)</cato:entity-ref> and
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:7" proposed="true">(a)(7)</cato:entity-ref>, if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> determines it is necessary to protect the public
				health, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may designate drug products or substances as described in
				such subsections, by—</text>
							<subparagraph id="H5D32F2318396422EA3D93D7184EDB393">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">publishing a notice of such drug products
				or substances proposed for designation, including the rationale for such
				designation, in the Federal Register;</text>
							</subparagraph>
              <subparagraph id="HA99978F6743742B6A8DEF7B747D396CB">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">providing a period of not less than 60
				calendar days for comment on the notice; and</text>
							</subparagraph>
              <subparagraph id="HFBDF0B2C1A8746AFBF2ED7A41454C70B">
                <enum>(C)</enum>
                <text display-inline="yes-display-inline">publishing a notice in the Federal Register
				designating such drug products or substances.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H06FE1960D30C497DA2AB828E2DDC1CA4">
              <enum>(4)</enum>
              <header>Updating
				lists</header>
              <text display-inline="yes-display-inline">The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall
				update the regulations containing the lists of drug products and substances
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A/cl:iii" proposed="true">subsections (a)(3)(A)(iii)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:7" proposed="true">(a)(7)</cato:entity-ref> regularly, but not less than
				once every three years.</text>
						</paragraph>
            <paragraph id="H973B523D73EB46479AAF6251453D787C">
              <enum>(5)</enum>
              <header>Sunset of
				notice</header>
              <text display-inline="yes-display-inline">Any notice published
				under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:e/p:3" proposed="true">paragraph (3)</cato:entity-ref> shall not be effective after the earlier of—</text>
							<subparagraph id="HCA24C69E08874E039EFC2AD08DE2DB39">
                <enum>(A)</enum>
                <text>the date that is 3
				years after the date of <short-title>
                    <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Compounding Clarity Act of 2013" proposed="true">Compounding Clarity
				Act of 2013</cato:entity-ref>
                  </short-title>; and</text>
							</subparagraph>
              <subparagraph id="HF5E2168DC5194D27BD6E56C910BC10A6">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">the effective date of the final regulations
				issued to implement <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3/sp:A/cl:iii" proposed="true">subsections (a)(3)(A)(iii)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:7" proposed="true">(a)(7)</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
          </subsection>
          <subsection id="H2C6742070FE24EC8809C223636A69AB9">
            <enum>(f)</enum>
            <header>Definitions</header>
            <text>In
				this section:</text>
						<paragraph id="H4B8301E3BFB9424FB3535445CEEBEDA2">
              <enum>(1)</enum>
              <text>The term
				<term>compounding</term> includes—</text>
							<subparagraph id="H2D6876802EFF4E7FA07007C367B65DE6">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">the combining, admixing, mixing, diluting,
				reconstituting, or otherwise altering of a marketed drug product, except when
				performed in accordance with specific directions for such acts contained in
				approved labeling provided by the product’s manufacturer or otherwise provided
				by that manufacturer consistent with that labeling;</text>
							</subparagraph>
              <subparagraph id="H6FCBD59D1C294F698921A8A6A3AEB2D6">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">the combining, admixing, mixing, diluting,
				reconstituting, or otherwise altering a bulk drug substance to create a drug
				product; and</text>
							</subparagraph>
              <subparagraph id="H09EA848000E9440FB431F8C34248751E">
                <enum>(C)</enum>
                <text display-inline="yes-display-inline">repackaging.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="HED2C144EE1814F62BE983D2C9ECBF7DE">
              <enum>(2)</enum>
              <text>The term
				<term>essentially a copy of a marketed and approved drug product</term> does
				not include—</text>
							<subparagraph id="H86C85FA5C637436C8917307F71A649FE">
                <enum>(A)</enum>
                <text>a drug product in
				which there is a change, made for an identified individual patient, which
				produces for that patient a clinical difference, as determined by the
				prescribing practitioner, between the compounded drug product and the
				comparable marketed and approved drug product; or</text>
							</subparagraph>
              <subparagraph id="HC6D140E7E6614D3C8F436AABE53B8070">
                <enum>(B)</enum>
                <text>a drug product
				that appears on the drug shortage list in effect under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506E">section 506E</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H60A3DCA14EE24AE7A0127100DD543695">
              <enum>(3)</enum>
              <text>The term
				<term>licensed pharmacist</term> includes any individual who compounds drug
				products under the supervision of a practitioner licensed to compound drug
				products under State law.</text>
						</paragraph>
            <paragraph id="HB35D5CC158DD4B9496DB565760F33CBA">
              <enum>(4)</enum>
              <text display-inline="yes-display-inline">The term <term>marketed and approved drug
				product</term> means a drug product that—</text>
							<subparagraph id="HD10003C549E146168A233062149A769E">
                <enum>(A)</enum>
                <text>is currently
				marketed; and</text>
							</subparagraph>
              <subparagraph id="H77D47FEAB781464EA646A96FD6C6E23A">
                <enum>(B)</enum>
                <text>is approved under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505 of this Act</cato:entity-ref> or licensed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health
				Service Act</cato:entity-ref>.</text>
							</subparagraph>
            </paragraph>
            <paragraph id="H44684B94951C462196412484695A9ECF">
              <enum>(5)</enum>
              <subparagraph commented="no" display-inline="yes-display-inline" id="HDB8A1F13CCEB4D32B473B61A0320D705">
                <enum>(A)</enum>
                <text display-inline="yes-display-inline">The term <term>repackaging</term> means
				taking a drug approved under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">section 505 of this Act</cato:entity-ref> or licensed under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section
				351 of the Public Health Service Act</cato:entity-ref> from the container in which the drug is
				distributed by the original manufacturer and placing such drug in a different
				container of the same or smaller size without further manipulating the drug
				(such as by diluting it or mixing it with another, different drug or
				drugs).</text>
							</subparagraph>
              <subparagraph id="H1C29372C896B4AFD9E7835C916DE52C4" indent="up1">
                <enum>(B)</enum>
                <text display-inline="yes-display-inline">Such term does not include removing the
				drug from its original container for immediate administration to an identified
				individual patient, such as withdrawing a drug into a syringe for immediate
				injection or removing the drug from its original container within a health care
				entity by a practitioner, or other licensed individual under the supervision or
				direction of such practitioner, for administration within the same day within
				such health care
				entity.</text>
							</subparagraph>
            </paragraph>
          </subsection>
        </section>
        <after-quoted-block>.</after-quoted-block>
      </quoted-block>
		</section>
    <section id="H0703424917A147D0B18F91703825BBEC">
      <enum>3.</enum>
      <header>Outsourcing
			 facilities</header>
			<subsection id="H3E3EF7E5C5FB4AF18D544A4880116067">
        <enum>(a)</enum>
        <header>In
			 general</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:V/sch:A">Subchapter A of
			 chapter V of the Federal Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/351">
              <cato:entity-ref entity-type="uscode" value="usc/21/351/etseq">21 U.S.C. 351 et seq.</cato:entity-ref>
            </external-xref>)</cato:entity>
			 is amended—</text>
				<paragraph id="HA35F85BD0A1B433586419B917BC01802">
          <enum>(1)</enum>
          <text>by redesignating
			 <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B">section 503B</cato:entity-ref> as <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503C" proposed="true">section 503C</cato:entity-ref>; and</text>
				</paragraph>
        <paragraph id="H87E8085C6697455BA438B89765447EB3">
          <enum>(2)</enum>
          <text>by inserting after
			 <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
              <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A">section 503A</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/353a">
                <cato:entity-ref entity-type="uscode" value="usc/21/353a">21 U.S.C. 353a</cato:entity-ref>
              </external-xref>)</cato:entity> the following new section:</text>
					<quoted-block display-inline="no-display-inline" id="HF8CB560F5B4E447A8C3193E91E025410" style="OLC">
						<section id="H982C2E77027943C286D40C3C02DDA2CE">
              <enum>503B.</enum>
              <header>Outsourcing
				facilities</header>
							<subsection id="H08E22E06E53E48B78109340A809F585C">
                <enum>(a)</enum>
                <header>In
				general</header>
                <text display-inline="yes-display-inline">
                  <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502/ss:f/p:1">Sections 502(f)(1)</cato:entity-ref>
				and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:505">505 of this Act</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Public Health Service Act/s:351">section 351 of the Public Health Service Act</cato:entity-ref> shall not
				apply to a drug product compounded for human use by a licensed pharmacist in an
				outsourcing facility if each of the following conditions is met:</text>
								<paragraph id="H0E8686EE979B49488DBC68443ED57243">
                  <enum>(1)</enum>
                  <header>Registration and
				reporting</header>
                  <text display-inline="yes-display-inline">The facility is in
				compliance with the registration and reporting requirements of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:b" proposed="true">subsection
				(b)</cato:entity-ref>.</text>
								</paragraph>
                <paragraph id="H7E3D51A8547E4AAF9B82730F9C1DEEE5">
                  <enum>(2)</enum>
                  <header>Drug product and
				substance limitations</header>
                  <text>The facility does not compound drug
				products in violation of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:3..8" proposed="true">paragraphs (3) through (8) of section 503A(a)</cato:entity-ref>.</text>
								</paragraph>
                <paragraph id="HA7F903E28068481EA44B08C93E7F11AB">
                  <enum>(3)</enum>
                  <header>Fees</header>
                  <text>The
				facility has paid all fees owed by such facility pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K">section 744K</cato:entity-ref>.</text>
								</paragraph>
                <paragraph id="H452302217B0541058552A32F94707179">
                  <enum>(4)</enum>
                  <header>Standardized
				drug products from bulk</header>
                  <text display-inline="yes-display-inline">The
				facility does not compound, from bulk drug substances, standardized dosages
				that are not otherwise commercially available of a marketed and approved drug
				product.</text>
								</paragraph>
                <paragraph id="H0646FE22A4EE490CB733EDDFAD60665C">
                  <enum>(5)</enum>
                  <header>Labeling of drug
				products</header>
									<subparagraph id="H8B9A7CBFAFC645EEB6C723C5C83D311A">
                    <enum>(A)</enum>
                    <header>Label</header>
                    <text display-inline="yes-display-inline">The label of a drug product compounded by
				an outsourcing facility shall include—</text>
										<clause id="H81455AC493424478B786F00B180B3701">
                      <enum>(i)</enum>
                      <text display-inline="yes-display-inline">the statement <quote>This is a compounded
				drug.</quote> or a reasonable comparable alternative statement (as specified by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>) that prominently identifies the drug as a compounded drug
				product;</text>
										</clause>
                    <clause id="H3567FB7664894D9693AF269B74354814">
                      <enum>(ii)</enum>
                      <text display-inline="yes-display-inline">the name, address, and phone number of the
				applicable outsourcing facility; and</text>
										</clause>
                    <clause id="HD71D0425482D472890567ACB5931C70D">
                      <enum>(iii)</enum>
                      <text display-inline="yes-display-inline">with respect to the compounded drug
				product—</text>
											<subclause id="H7F7B781D50D641E8BB9FF386E069A1D4">
                        <enum>(I)</enum>
                        <text display-inline="yes-display-inline">the lot or batch number;</text>
											</subclause>
                      <subclause id="H052AD2929A6F4966AD5001734A37EFA7">
                        <enum>(II)</enum>
                        <text display-inline="yes-display-inline">the established name of the drug
				product;</text>
											</subclause>
                      <subclause id="H6B206D14A3CB4B5992A9658B27DF362C">
                        <enum>(III)</enum>
                        <text display-inline="yes-display-inline">the dosage form and strength;</text>
											</subclause>
                      <subclause id="H4335E6AD87904515B6681DFB81381C74">
                        <enum>(IV)</enum>
                        <text display-inline="yes-display-inline">the statement of quantity or volume, as
				appropriate;</text>
											</subclause>
                      <subclause id="H07A01B7BB6464CF5936F92A8FA7F3EF3">
                        <enum>(V)</enum>
                        <text display-inline="yes-display-inline">the date that the drug product was
				compounded;</text>
											</subclause>
                      <subclause id="H5837DD540289400D8FE6E094F51A709D">
                        <enum>(VI)</enum>
                        <text display-inline="yes-display-inline">the expiration date;</text>
											</subclause>
                      <subclause id="H32A99ABFF72F4A03B6B823C780AE931F">
                        <enum>(VII)</enum>
                        <text display-inline="yes-display-inline">storage and handling instructions;</text>
											</subclause>
                      <subclause id="H2BB23753D66A4007B0DEE7C6CE829135">
                        <enum>(VIII)</enum>
                        <text display-inline="yes-display-inline">the National Drug Code number, if
				available;</text>
											</subclause>
                      <subclause id="H463B4C528CC747029E1FBB0232689F41">
                        <enum>(IX)</enum>
                        <text display-inline="yes-display-inline">the <term>Not for resale</term> statement
				required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:C/cl:v" proposed="true">section 503A(a)(1)(C)(v)</cato:entity-ref>; and</text>
											</subclause>
                      <subclause id="HEBAB475718F9413DB88E0453B376C4C0">
                        <enum>(X)</enum>
                        <text display-inline="yes-display-inline">subject to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:a/p:5/sp:B/cl:i" proposed="true">subparagraph (B)(i)</cato:entity-ref>, a list of
				active and inactive ingredients, identified by established name and the
				quantity or proportion of each ingredient.</text>
											</subclause>
                    </clause>
                  </subparagraph>
                  <subparagraph id="H313CB63230484A0183DE8C51028DB020">
                    <enum>(B)</enum>
                    <header>Container</header>
                    <text display-inline="yes-display-inline">The container from which the individual
				units of a drug product compounded by an outsourcing facility are removed for
				dispensing or for administration (such as a plastic bag containing individual
				product syringes) shall include—</text>
										<clause id="H3BE02B42F01B491494D515B17EE42624">
                      <enum>(i)</enum>
                      <text display-inline="yes-display-inline">the information described under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:a/p:5/sp:A/cl:iii/scl:X" proposed="true">subparagraph (A)(iii)(X)</cato:entity-ref>, if there is not space on the label for such
				information;</text>
										</clause>
                    <clause id="H04EA333154F94665A53EA97566EEB7AC">
                      <enum>(ii)</enum>
                      <text display-inline="yes-display-inline">the following information to facilitate
				adverse event reporting: www.fda.gov/medwatch and 1–800–FDA–1088; and</text>
										</clause>
                    <clause id="H7B3AAE43FBDE4C94BCC9F16F619309BD">
                      <enum>(iii)</enum>
                      <text display-inline="yes-display-inline">directions for use, including, as
				appropriate, dosage and administration.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="H1D4E6A6AF21848C28077A9FDD08FE237">
                    <enum>(C)</enum>
                    <header>Additional
				information</header>
                    <text display-inline="yes-display-inline">The label and
				labeling of a drug product compounded by an outsourcing facility shall include
				any other information as determined necessary and specified in regulations
				promulgated by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
                    </text>
									</subparagraph>
                </paragraph>
              </subsection>
              <subsection id="H1BEB0849D7D344D19F8C8EBDB8FF4CAE">
                <enum>(b)</enum>
                <header>Registration of
				outsourcing facilities and reporting of drug products</header>
								<paragraph id="HEE60E8E721884A52837C191B6033C15B">
                  <enum>(1)</enum>
                  <header>Registration of
				outsourcing facilities</header>
									<subparagraph id="HB4F4F0C2BEFF4FA892B48FFE008A08D7">
                    <enum>(A)</enum>
                    <header>Annual
				registration</header>
                    <text display-inline="yes-display-inline">During the
				period beginning on October 1 and ending on December 31 each year, each
				outsourcing facility—</text>
										<clause id="H780306BCEA474518A95CAD23F987770D">
                      <enum>(i)</enum>
                      <text>shall register
				with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> its name, place of business, and unique facility identifier
				(which shall conform to the requirements for the unique facility identifier
				established under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:510">section 510</cato:entity-ref>), and a point of contact e-mail address;
				and</text>
										</clause>
                    <clause id="H729D51628B2A40B393BD363C668F53E1">
                      <enum>(ii)</enum>
                      <text>shall indicate
				whether the out­sourc­ing facility intends to compound a drug product that
				appears on the list in effect under section 506E during the subsequent calendar
				year.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="H42887C1EB53F4B2593DF95F350044FDF">
                    <enum>(B)</enum>
                    <header>New outsourcing
				facilities</header>
                    <text display-inline="yes-display-inline">Each outsourcing
				facility, upon first engaging in compounding pursuant to this section, shall
				immediately register with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> and provide the information described
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:b/p:1/sp:A" proposed="true">paragraph (1)(A)</cato:entity-ref>. The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall establish a timeline for registration
				for the first calendar year following the effective date of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Compounding Clarity Act of 2013" proposed="true">Compounding
				Clarity Act of 2013</cato:entity-ref>. In no case may registration be required until at least 60
				calendar days following publication of the timeline in the Federal
				Register.</text>
									</subparagraph>
                  <subparagraph id="H61A6808B429B4FE0861850CB6392561C">
                    <enum>(C)</enum>
                    <header>Availability of
				registration for inspection; list</header>
										<clause id="HCCD356C801E4475F99BDAD05D1A46158">
                      <enum>(i)</enum>
                      <header>Registrations</header>
                      <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make available for inspection, to any person so requesting, any
				registration filed pursuant to this paragraph.</text>
										</clause>
                    <clause id="H02633FE9762048BFBA2DD440068B6CBE">
                      <enum>(ii)</enum>
                      <header>List</header>
                      <text>The
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make available on the public Internet Web site of the Food and
				Drug Administration a list of the name of each facility registered under this
				subsection as an outsourcing facility, the State in which each such facility is
				located, whether the facility compounds from bulk drug substances, and whether
				any such compounding from bulk drug substances is for sterile or non-sterile
				drug products.</text>
										</clause>
                  </subparagraph>
                </paragraph>
                <paragraph id="H8D17D3ADBB7B41FA8BC993B98A605CDD">
                  <enum>(2)</enum>
                  <header>Drug product
				reporting by outsourcing facilities</header>
									<subparagraph id="H81AA7FB0351A4F46A97528F6CC49CDB2">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text display-inline="yes-display-inline">Upon initially
				registering as an outsourcing facility, once during the month of June of each
				year, and once during the month of December of each year, each outsourcing
				facility that registers with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:b/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall submit to
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a report—</text>
										<clause id="H946885D19F8D4938B55519A3E240CADE">
                      <enum>(i)</enum>
                      <text>identifying the
				drug products compounded by such outsourcing facility during the previous
				6-month period; and</text>
										</clause>
                    <clause id="HF327BDC39D10467E8C09DC60A2E0F6E3">
                      <enum>(ii)</enum>
                      <text>with respect to
				each drug product identified under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:b/p:2/sp:A/cl:i" proposed="true">clause (i)</cato:entity-ref>, providing the active ingredient;
				the source of such active ingredient; the National Drug Code number, if
				available, of the source drug product or bulk active ingredient; the strength
				of the active ingredient per unit; the dosage form and route of administration;
				the package description; the number of individual units produced; and the
				National Drug Code number of the final product, if assigned.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="H772D6EBA0A6A4469B69D023ED8815FBA">
                    <enum>(B)</enum>
                    <header>Form</header>
                    <text>Each
				report under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:b/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref> shall be prepared in such form and manner as the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> may prescribe by regulation or guidance.</text>
									</subparagraph>
                  <subparagraph id="H731FCDF19F854AEABF171E39B91135D9">
                    <enum>(C)</enum>
                    <header>Confidentiality</header>
                    <text>Reports
				submitted under this paragraph shall be exempt from inspection under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:b/p:1/sp:C" proposed="true">paragraph
				(1)(C)</cato:entity-ref>, unless the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> finds that such an exemption would be inconsistent
				with the protection of the public health.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="HDD292B52B3BD45369238DA4000C362EF">
                  <enum>(3)</enum>
                  <header>Electronic
				registration and reporting</header>
                  <text>Registrations and drug product
				reporting under this subsection (including the submission of updated
				information) shall be submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by electronic means unless the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> grants a request for waiver of such requirement because use of
				electronic means is not reasonable for the person requesting waiver.</text>
								</paragraph>
                <paragraph id="HFA5CC7BB996A41A399E7D939D1C3DBB3">
                  <enum>(4)</enum>
                  <header>Risk-based
				inspection frequency</header>
									<subparagraph id="HDE65618E71FA437B9BBD692B13AD6EFE">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>Outsourcing facilities—</text>
										<clause id="HF75AF74698FD4A919DB771B27047F556">
                      <enum>(i)</enum>
                      <text>shall be subject
				to inspection pursuant to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704">section 704</cato:entity-ref>; and</text>
										</clause>
                    <clause id="H47D3E1F88E92452B96EF5B9356B040E1">
                      <enum>(ii)</enum>
                      <text>shall not be
				eligible for the exemption under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704/ss:a/p:2/sp:A">section 704(a)(2)(A)</cato:entity-ref>.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="H0C68477737BB4E398935B8E1EEA5A6B4">
                    <enum>(B)</enum>
                    <header>Risk-based
				schedule</header>
                    <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, acting through one or more officers or
				employees duly designated by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>, shall inspect outsourcing
				facilities in accordance with a risk-based schedule established by the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>.</text>
									</subparagraph>
                  <subparagraph id="HA2BBFBFF1BAB40F1841D1A64CBEEF3B0">
                    <enum>(C)</enum>
                    <header>Risk
				factors</header>
                    <text>In establishing the risk-based schedule, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall inspect outsourcing facilities according to the known safety risks of
				such outsourcing facilities, which shall be based on the following
				factors:</text>
										<clause id="H4246C8FC7C2E4515A8D15571F7023662">
                      <enum>(i)</enum>
                      <text>The compliance
				history of the outsourcing facility.</text>
										</clause>
                    <clause id="H7E49B224033C4EDCB0B2F0D3254410FE">
                      <enum>(ii)</enum>
                      <text>The record,
				history, and nature of recalls linked to the outsourcing facility.</text>
										</clause>
                    <clause id="H7ABAC6A832844E29A19AE48EC250E6AE">
                      <enum>(iii)</enum>
                      <text>The inherent
				risk of the drug products compounded at the outsourcing facility.</text>
										</clause>
                    <clause id="HDB81A87DCF6F43758E34694F8CC45817">
                      <enum>(iv)</enum>
                      <text>The inspection
				frequency and history of the outsourcing facility, including whether the
				outsourcing facility has been inspected pursuant to section 704 within the last
				4 years.</text>
										</clause>
                    <clause id="HAE1D8EBF6EF34898BE4FF55BEC4D9D34">
                      <enum>(v)</enum>
                      <text>Whether the
				outsourcing facility has registered under this paragraph as an entity that
				intends to compound a drug product that appears on the list in effect under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:506E">section 506E</cato:entity-ref>.</text>
										</clause>
                    <clause id="HDF44104A149444588ECF34EA4DE2195A">
                      <enum>(vi)</enum>
                      <text>Any other
				criteria deemed necessary and appropriate by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for purposes of
				allocating inspection resources.</text>
										</clause>
                  </subparagraph>
                </paragraph>
                <paragraph id="HE2695A95F47B4523B665D5DD565D0DBA">
                  <enum>(5)</enum>
                  <header>Adverse event
				reporting</header>
                  <text display-inline="yes-display-inline">Outsourcing
				facilities shall be required to submit adverse event reports to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				in accordance with the content and format requirements established through
				guidance or regulation under <external-xref legal-doc="usc" parsable-cite="usc/21/310">section 310.305</external-xref> of title 21, Code of Federal
				Regulations (or any successor regulations) or <external-xref legal-doc="usc" parsable-cite="usc/21/600">section 600.80</external-xref> of title 21, Code
				of Federal Regulations (or any successor regulations).</text>
								</paragraph>
              </subsection>
              <subsection id="H428494251FFA41A1A0F8B1F9885B464A">
                <enum>(c)</enum>
                <header>Definitions</header>
                <text>In
				this section:</text>
								<paragraph id="HDDEF64A872F54904B0B0498772E1EB54">
                  <enum>(1)</enum>
                  <header>Outsourcing
				facility</header>
                  <text display-inline="yes-display-inline">The term
				<term>outsourcing facility</term> means a facility at one geographic location
				or address that compounds sterile drug products for office use in excess of the
				limitation set forth in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:C/cl:iii" proposed="true">section 503A(a)(1)(C)(iii)</cato:entity-ref>.</text>
								</paragraph>
                <paragraph id="H1C7CFE62E783448AB58C8588FF20D950">
                  <enum>(2)</enum>
                  <header>Other
				definitions</header>
                  <text>The terms <term>compounding</term>, <term>essentially
				a copy of a marketed and approved drug product</term>, <term>licensed
				pharmacist</term>, and <term>marketed and approved drug product</term> have the
				meanings given such terms in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A/ss:f" proposed="true">section 503A(f)</cato:entity-ref>.</text>
								</paragraph>
              </subsection>
            </section>
            <after-quoted-block>.</after-quoted-block>
          </quoted-block>
				</paragraph>
      </subsection>
      <subsection id="H6ACE05EA5B064FE2996D346BB7AD90B2">
        <enum>(b)</enum>
        <header>Fees</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/ch:VII/sch:C">Subchapter C of chapter VII of the Federal
			 Food, Drug, and Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/379f">
              <cato:entity-ref entity-type="uscode" value="usc/21/379f/etseq">21 U.S.C. 379f et seq.</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by adding at
			 the end the following:</text>
				<quoted-block display-inline="no-display-inline" id="H9A00E29E83E24B68AF6EA1D4E9AB19FF" style="OLC">
					<part id="H68E9D3DCC9124856AA05316E8E567727">
            <enum>9</enum>
            <header>Fees
				relating to outsourcing facilities</header>
						<section id="HF6CADABF342B48FD85BB37D48FE34399">
              <enum>744J.</enum>
              <header>Definitions</header>
              <text display-inline="no-display-inline">In this part:</text>
							<paragraph id="HFFF42BE8CAD9404DBF37791BB54D0B13">
                <enum>(1)</enum>
                <text>The term
				<term>affiliate</term> has the meaning given such term in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:735/p:11">section
				735(11)</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="H1C75E8830C0B4003B29EA44BE610191A">
                <enum>(2)</enum>
                <text>The term
				<term>gross annual sales</term> means the total worldwide gross annual sales,
				in United States dollars, for an outsourcing facility, including the sales of
				all the affiliates of the outsourcing facility.</text>
							</paragraph>
              <paragraph id="H09C57C29FBCF4B7885B8F5AB59579F71">
                <enum>(3)</enum>
                <text>The term
				<term>outsourcing facility</term> has the meaning given to such term in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:c" proposed="true">section
				503B(c)</cato:entity-ref>.</text>
							</paragraph>
              <paragraph id="H44D97FB755234E7B92629EDDD6EA3460">
                <enum>(4)</enum>
                <text>The term
				<term>reinspection</term> means, with respect to an outsourcing facility, one
				or more inspections conducted under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:704">section 704</cato:entity-ref> subsequent to an inspection
				conducted under such provision which identified noncompliance materially
				related to an applicable requirement of this Act, specifically to determine
				whether compliance has been achieved to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary’s</cato:entity-ref> satisfaction.</text>
							</paragraph>
            </section>
            <section id="HAEBDFFFCDA8844A7B2C60C40CB65842E">
              <enum>744K.</enum>
              <header>Authority to
				assess and use outsourcing facility fees</header>
							<subsection id="H51ACD15A551F47689867AF796A56138A">
                <enum>(a)</enum>
                <header>Establishment
				and reinspection fees</header>
                <text>—</text>
								<paragraph id="H3F561692B28641F2A3CC2BFF93F050C8">
                  <enum>(1)</enum>
                  <header>In
				general</header>
                  <text>For fiscal year 2015 and each subsequent fiscal year, the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall, in accordance with this subsection, assess and collect—</text>
									<subparagraph id="HA79E6BB626714683948C5EF7A79A8FB4">
                    <enum>(A)</enum>
                    <text>an annual
				establishment fee from each outsourcing facility; and</text>
									</subparagraph>
                  <subparagraph id="H8F46CB403FE24B0189D4B952129F20FC">
                    <enum>(B)</enum>
                    <text>a reinspection fee
				from each outsourcing facility subject to a reinspection in such fiscal
				year.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="HA0F18EEF86EA4E1684F32D2C5AD58E17">
                  <enum>(2)</enum>
                  <header>Multiple
				reinspections</header>
                  <text>An outsourcing facility subject to multiple
				reinspections in a fiscal year shall be subject to a reinspection fee for each
				reinspection.</text>
								</paragraph>
              </subsection>
              <subsection id="HFB79A726B198448AA5C7C7A376EF68CD">
                <enum>(b)</enum>
                <header>Establishment
				and reinspection fee setting</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
								<paragraph id="HD8F85BB127904DF8B67A8EE23517C80E">
                  <enum>(1)</enum>
                  <text>establish the
				amount of the establishment and reinspection fee to be collected under this
				section for each fiscal year based on the methodology described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c" proposed="true">subsection
				(c)</cato:entity-ref>; and</text>
								</paragraph>
                <paragraph id="HCBD33B785F9F43AF9E2F995110AE83B4">
                  <enum>(2)</enum>
                  <text>publish such fee
				amounts in a Federal Register notice not later than 60 calendar days before the
				start of each such year.</text>
								</paragraph>
              </subsection>
              <subsection id="H4C14EA23FA9D49D1A9DCECE8586F81AE">
                <enum>(c)</enum>
                <header>Amount of
				establishment fee and reinspection fee</header>
								<paragraph id="H9CB96C7D429C45D4979181EB62ED941F">
                  <enum>(1)</enum>
                  <header>In
				general</header>
                  <text>For each outsourcing facility in a fiscal year—</text>
									<subparagraph id="H5363C70CB39F4E7781CD34020E654659">
                    <enum>(A)</enum>
                    <text>except as provided
				in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c/p:4" proposed="true">paragraph (4)</cato:entity-ref>, the amount of the annual establishment fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:b" proposed="true">subsection
				(b)</cato:entity-ref> shall be equal to the sum of—</text>
										<clause id="HCAC9A060F11F433E9A13ED0B55F99236">
                      <enum>(i)</enum>
                      <text>$15,000,
				multiplied by the inflation adjustment factor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c/p:2" proposed="true">paragraph (2)</cato:entity-ref>;
				plus</text>
										</clause>
                    <clause id="HF15519671EB24ACABDDA23AA29557240">
                      <enum>(ii)</enum>
                      <text>the small
				business adjustment factor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c/p:3" proposed="true">paragraph (3)</cato:entity-ref>; and</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="H3F927571B2CD4A5BA955A25365952A4D">
                    <enum>(B)</enum>
                    <text>the amount of any
				reinspection fee (if applicable) under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:b" proposed="true">subsection (b)</cato:entity-ref> shall be equal to
				$15,000, multiplied by the inflation adjustment factor described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c/p:3" proposed="true">paragraph
				(3)</cato:entity-ref>.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="H8E16EFC487EE4E04920F99CC3D8F239C">
                  <enum>(2)</enum>
                  <header>Inflation
				adjustment factor</header>
									<subparagraph id="HA9ED69CBC4E94DA3A909C77708521A43">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>For fiscal year 2015 and subsequent fiscal years, the fee
				amounts established in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c/p:1" proposed="true">paragraph (1)</cato:entity-ref> shall be adjusted by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> by
				notice, published in the Federal Register, for a fiscal year by the amount
				equal to the sum of—</text>
										<clause id="H46C0EECC2B5946D1B9C883E850BF2164">
                      <enum>(i)</enum>
                      <text>one;</text>
										</clause>
                    <clause id="HCA09A524E4F94190B34A82EA6EB8180C">
                      <enum>(ii)</enum>
                      <text>the average
				annual percent change in the cost, per full-time equivalent position of the
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref>, of all personnel compensation and benefits paid
				with respect to such positions for the first 3 years of the preceding 4 fiscal
				years, multiplied by the proportion of personnel compensation and benefits
				costs to total costs of an average full-time equivalent position of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
				and Drug Administration</cato:entity-ref> for the first 3 years of the preceding 4 fiscal years;
				and</text>
										</clause>
                    <clause id="H002ED734CFB54D15BE1DC60C753634B8">
                      <enum>(iii)</enum>
                      <text>the average
				annual percent change that occurred in the Consumer Price Index for urban
				consumers (U.S. City Average; Not Seasonally Adjusted; All items; Annual Index)
				for the first 3 years of the preceding 4 years of available data multiplied by
				the proportion of all costs other than personnel compensation and benefits
				costs to total costs of an average full-time equivalent position of the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food
				and Drug Administration</cato:entity-ref> for the first 3 years of the preceding 4 fiscal
				years.</text>
										</clause>
                  </subparagraph>
                  <subparagraph id="HAAF61DDC243548B3B552A6673D34C60B">
                    <enum>(B)</enum>
                    <header>Compounded
				basis</header>
                    <text>The adjustment made each fiscal year under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>
				shall be added on a compounded basis to the sum of all adjustments made each
				fiscal year after fiscal year 2014 under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c/p:2/sp:A" proposed="true">subparagraph (A)</cato:entity-ref>.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="H76739D4813424D28BFD296C443D98EC9">
                  <enum>(3)</enum>
                  <header>Small business
				adjustment factor</header>
                  <text>The small business adjustment factor referred
				to in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c/p:1/sp:A/cl:ii" proposed="true">paragraph (1)(A)(ii)</cato:entity-ref> shall be an amount established by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> for
				each fiscal year based on the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary’s</cato:entity-ref> estimate of—</text>
									<subparagraph id="H12B3EC8101F8434D9E1EB4327C32E0F3">
                    <enum>(A)</enum>
                    <text>the number of
				small businesses that will pay a reduced establishment fee for such fiscal
				year; and</text>
									</subparagraph>
                  <subparagraph id="HA892F6CAA0B6411BBB3CAC70274C717E">
                    <enum>(B)</enum>
                    <text>the adjustment to
				the establishment fee necessary to achieve total fees equaling the total fees
				that the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> would have collected if no entity qualified for the small
				business exception in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c/p:4" proposed="true">paragraph (4)</cato:entity-ref>.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="H21B74FCDA1BB4E51AC3E7F9DD251AB05">
                  <enum>(4)</enum>
                  <header>Exception for
				small businesses</header>
									<subparagraph id="HB80FAF3A39A34951974B3DAD7EB6F8AE">
                    <enum>(A)</enum>
                    <header>In
				general</header>
                    <text>In the case of an outsourcing facility with gross annual
				sales of $1,000,000 or less in the 12 months ending April 1 of the fiscal year
				immediately preceding the fiscal year in which the fees under this section are
				assessed, the amount of the establishment fee under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:b" proposed="true">subsection (b)</cato:entity-ref> for a fiscal
				year shall be equal to <fraction>1/3</fraction> of the amount calculated under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c/p:1/sp:A/cl:i" proposed="true">paragraph (1)(A)(i)</cato:entity-ref> for such fiscal year.</text>
									</subparagraph>
                  <subparagraph id="H239EBFEFF2C84F89A4593DD95C5FEAD1">
                    <enum>(B)</enum>
                    <header>Application</header>
                    <text>To
				qualify for the exception under this paragraph, a small business shall submit
				to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> a written request for such exception, in a format specified by
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> in guidance, certifying its gross annual sales for the 12 months
				ending April 1 of the fiscal year immediately preceding the fiscal year in
				which fees under this subsection are assessed. Any such application shall be
				submitted to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> not later than April 30 of such immediately
				preceding fiscal year.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="H50E8D04F6A0A44A182A4D94E685F6185">
                  <enum>(5)</enum>
                  <header>Crediting of
				fees</header>
                  <text>In establishing the small business adjustment factor under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:c/p:3" proposed="true">paragraph (3)</cato:entity-ref> for a fiscal year, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall—</text>
									<subparagraph id="HA564DA3200C44CBCBFEB89778DA786DF">
                    <enum>(A)</enum>
                    <text>provide for the
				crediting of fees from the previous year to the next year if the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				overestimated the amount of the small business adjustment factor for such
				previous fiscal year; and</text>
									</subparagraph>
                  <subparagraph id="H69252CFD2D1848D8A3B4ABA30063C1D6">
                    <enum>(B)</enum>
                    <text>consider the need
				to account for any adjustment of fees and such other factors as the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				determines appropriate.</text>
									</subparagraph>
                </paragraph>
              </subsection>
              <subsection id="H43303A6C94C24009882E6D058B87D59C">
                <enum>(d)</enum>
                <header>Use of
				fees</header>
                <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall make all of the fees collected pursuant
				to <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:a/p:1/sp:A" proposed="true">subparagraphs (A)</cato:entity-ref> and <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:a/p:1/sp:B" proposed="true">(B) of subsection (a)(1)</cato:entity-ref> available solely to pay for
				the costs of oversight of outsourcing facilities.</text>
							</subsection>
              <subsection id="H6D50C0863EDB4FBA84E6CDFA5013CF24">
                <enum>(e)</enum>
                <header>Supplement not
				supplant</header>
                <text>Funds received by the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> pursuant to this section
				shall be used to supplement and not supplant any other Federal funds available
				to carry out the activities described in this section.</text>
							</subsection>
              <subsection id="HA16CF21777FC41E08620B49BEB3CC5E4">
                <enum>(f)</enum>
                <header>Crediting and
				availability of fees</header>
                <text>Fees authorized under this section shall be
				collected and available for obligation only to the extent and in the amount
				provided in advance in appropriations Acts. Such fees are authorized to remain
				available until expended. Such sums as may be necessary may be transferred from
				the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7524">Food and Drug Administration</cato:entity-ref> salaries and expenses appropriation account
				without fiscal year limitation to such appropriation account for salaries and
				expenses with such fiscal year limitation. The sums transferred shall be
				available solely for the purpose of paying the costs of oversight of
				outsourcing facilities.</text>
							</subsection>
              <subsection id="H6D67D120A2BC40BEA35D5CFB2F9BA641">
                <enum>(g)</enum>
                <header>Collection of
				fees</header>
								<paragraph id="HB3259CE825F84029BB349994C84E69E3">
                  <enum>(1)</enum>
                  <header>Establishment
				fee</header>
                  <text>An outsourcing facility shall remit the establishment fee due
				under this section in a fiscal year when submitting a registration pursuant to
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:b" proposed="true">section 503B(b)</cato:entity-ref> for such fiscal year.</text>
								</paragraph>
                <paragraph id="HC606E6F9DA034BBEA2FE34962A43E71B">
                  <enum>(2)</enum>
                  <header>Reinspection
				fee</header>
                  <text>The <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> shall specify in the Federal Register notice
				described in <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K/ss:b/p:2" proposed="true">subsection (b)(2)</cato:entity-ref> the manner in which reinspection fees assessed
				under this section shall be collected and the timeline for payment of such
				fees. Such a fee shall be collected after the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> has conducted a
				reinspection of the outsourcing facility involved.</text>
								</paragraph>
                <paragraph id="HC5034754CEDD4762A6A960B8E6AFD92B">
                  <enum>(3)</enum>
                  <header>Effect of
				failure to pay fees</header>
									<subparagraph id="H42997030E26F4262A35A912C72877A4A">
                    <enum>(A)</enum>
                    <header>Registration</header>
                    <text>An
				outsourcing facility shall not be considered registered under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:b" proposed="true">section 503B(b)</cato:entity-ref>
				in a fiscal year until the date that the outsourcing facility remits the
				establishment fee under this subsection for such fiscal year.</text>
									</subparagraph>
                  <subparagraph id="H85E315EC490D4C279CF5FCC8C100E33A">
                    <enum>(B)</enum>
                    <header>Misbranding</header>
                    <text>All
				drug products manufactured, prepared, propagated, compounded, or processed by
				an outsourcing facility for which any establishment fee or reinspection fee has
				not been paid, as required by this section, shall be deemed misbranded under
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:502">section 502</cato:entity-ref> until the fees owed for such outsourcing facility under this
				section have been paid.</text>
									</subparagraph>
                </paragraph>
                <paragraph id="H71EBCDA4CB2D4539BE52EA44214DE9DC">
                  <enum>(4)</enum>
                  <header>Collection of
				unpaid fees</header>
                  <text>In any case where the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> does not receive
				payment of a fee assessed under this section within 30 calendar days after it
				is due, such fee shall be treated as a claim of the United States Government
				subject to provisions of <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="uscode" value="usc-chapter/31/37/II">subchapter II of <external-xref legal-doc="usc-chapter" parsable-cite="usc-chapter/31/37">chapter 37</external-xref> of title 31, United States
				Code</cato:entity-ref>.</text>
								</paragraph>
              </subsection>
              <subsection id="H39A7D9A6CFE14F4C9EF2B7D6C295E1A5">
                <enum>(h)</enum>
                <header>Annual report to
				Congress</header>
                <text>Not later than 120 calendar days after each fiscal year
				in which fees are assessed and collected under this section, the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref>
				shall submit a report to the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="SSHR00">Committee on Health, Education, Labor, and
				Pensions of the Senate</cato:entity-ref> and the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="committee" entity-id="HIF00">Committee on Energy and Commerce of the House of
				Representatives</cato:entity-ref>, to include a description of fees assessed and collected for
				such year, a summary description of entities paying the fees, a description of
				the hiring and placement of new staff, a description of the use of fee
				resources to support inspecting outsourcing facilities, and the number of
				inspections and reinspections of such facilities performed each year.</text>
							</subsection>
              <subsection id="H44AC35543B1844AC9DBFFE17FE666FA2">
                <enum>(i)</enum>
                <header>Authorization of
				appropriations</header>
                <text>
                  <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="auth-auth-approp">
                    <cato:funds-and-year amount="indefinite" year="2015,..">For fiscal year 2015 and each subsequent fiscal
				year</cato:funds-and-year>, there is authorized to be appropriated <cato:property name="purpose">for fees under <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:744K" proposed="true">this subsection</cato:entity-ref>
                    </cato:property> an
				amount equivalent to the total amount of fees assessed for such fiscal year
				under this section.</cato:entity>
                </text>
							</subsection>
            </section>
          </part>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
    </section>
    <section id="H5AF6F55F64DC45DD9E725EC2CBFE1A6E">
      <enum>4.</enum>
      <header>Prohibited
			 acts</header>
			<subsection id="HCA8D845EC38C451EA5A121A411C647F9">
        <enum>(a)</enum>
        <header>Intentional
			 falsification of prescription order for compounded drug product</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301">Section 301 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/331">
              <cato:entity-ref entity-type="uscode" value="usc/21/331">21 U.S.C. 331</cato:entity-ref>
            </external-xref>)</cato:entity> is amended by inserting after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/p:bbb">paragraph (bbb)</cato:entity-ref> the
			 following:</text>
				<quoted-block display-inline="no-display-inline" id="H408062BD546943C5828CDF2CC9F99E79" style="OLC">
					<subsection id="HBE6D26231EB1402EB870EF282A5EA4DE">
            <enum>(ccc)</enum>
            <text display-inline="yes-display-inline">With respect to a drug product to be
				compounded under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A" proposed="true">section 503A</cato:entity-ref> or <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B" proposed="true">503B</cato:entity-ref>, the intentional falsification of a
				prescription, a purchase order, or patient name required under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503A" proposed="true">section 503A</cato:entity-ref> or
				<cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B" proposed="true">503B</cato:entity-ref>.</text>
					</subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
      <subsection id="H5F742B84FEEE414FAFBC57F3C695DF2B">
        <enum>(b)</enum>
        <header>Intentional
			 failure of outsourcing facility To register</header>
        <text display-inline="yes-display-inline">
          <cato:entity xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="law-citation">
            <cato:entity-ref entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301">Section 301 of the Federal Food, Drug, and
			 Cosmetic Act</cato:entity-ref> (<external-xref legal-doc="usc" parsable-cite="usc/21/331">
              <cato:entity-ref entity-type="uscode" value="usc/21/331">21 U.S.C. 331</cato:entity-ref>
            </external-xref>)</cato:entity>, as amended by <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Compounding Clarity Act of 2013/s:4/ss:a" proposed="true">subsection (a)</cato:entity-ref>, is further amended
			 by inserting after <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:301/p:ccc">paragraph (ccc)</cato:entity-ref> (as added by such subsection), the
			 following:</text>
				<quoted-block display-inline="no-display-inline" id="H5C022E641B484583AE5B6B37C77E834B" style="OLC">
					<subsection id="HFD4449B7BBA14102B3862EAF55B57562">
            <enum>(ddd)</enum>
            <text display-inline="yes-display-inline">With respect to any year in which an
				outsourcing facility is required to register with the <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="federal-body" entity-id="7500">Secretary</cato:entity-ref> under <cato:entity-ref xmlns:cato="http://namespaces.cato.org/catoxml" entity-type="act" value="Federal Food, Drug, and Cosmetic Act/s:503B/ss:b" proposed="true">section
				503B(b)</cato:entity-ref>, the intentional failure of the outsourcing facility to so
				register.</text>
					</subsection>
          <after-quoted-block>.</after-quoted-block>
        </quoted-block>
			</subsection>
    </section>
  </legis-body>
</bill>
</doc>